Live News EQUITY FLASH M impact Nov 17, 2026, 09:45 PM UTC Biogen’s Diranersen Slows Alzheimer’s Clinical Decline 38% in Phase 2 Study Diranersen slowed Alzheimer’s clinical decline by 38% at two years in a Phase 2 study. BIIB SquawkNews Desk